March 15, 2018 / 12:26 PM / Updated 36 minutes ago

BRIEF-Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer

Reuters Staff

1 Min Read

March 15 (Reuters) - Johnson & Johnson:

* JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ERDAFITINIB IN THE TREATMENT OF METASTATIC UROTHELIAL CANCER

* JANSSEN PHARMACEUTICAL - BREAKTHROUGH THERAPY DESIGNATION BASED ON DATA FROM MULTICENTER, OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ERDAFITINIB Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.